Company
Zai Lab
Zai Lab has 24 drugs tracked on RxWires: 5 in Phase 3, 7 in Phase 2, 1 in Phase 1/2, 10 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| ZL-2306 (Nirapairb) | Phase 3 | Ovarian Cancer |
| Omadacycline | Phase 3 | Community-acquired Bacterial Pneumonia |
| ZL-1310 | Phase 3 | Small-cell Lung Cancer |
| ZL-1109 (VRDN-003) | Phase 3 | Thyroid Eye Disease (TED) |
| ZL-1310 in combination with Atezolizumab or Durvalumab | Phase 3 | Extensive-Stage Small Cell Lung Cancer |
| ZL-2306(Niraparib） | Phase 2 | Ovarian Cancer |
| ZL-3101 | Phase 2 | Eczema |
| Margetuximab | Phase 2 | Breast Cancer Metastatic |
| Niraparib | Phase 2 | Endometrial Carcinoma |
| DCC-2618 | Phase 2 | Gastrointestinal Stromal Tumors |
| Brivanib 800 mg, QD | Phase 2 | Hepatocellular Carcinoma (HCC) |
| Ripretinib | Phase 2 | Gastrointestinal Stromal Tumor(GIST) |
| MGD013 monotherapy | Phase 1/2 | Advanced Hepatocellular Carcinoma (HCC) |
| MRTX849 | Phase 1 | Advanced or Metastatic Solid Tumor |
| Moxifloxacin Oral Tablet | Phase 1 | Healthy Volunteer |
| ZL-1503 | Phase 1 | Healthy Volunteers |
| Niraparib combined with MGD013 | Phase 1 | Gastric Cancer |
| Tisotumab Vedotin | Phase 1 | Solid Malignancies |
| Margetuximab Margetuximab-IV | Phase 1 | HER2 Positive Metastatic Breast Cancer |
| ZL-1218 | Phase 1 | Malignant Solid Tumor |
| MGD013 | Phase 1 | Unresectable, Recurrent or Metastatic Melanoma |
| ZL-1201 | Phase 1 | Advanced Cancer |
| ZL-6201 | Phase 1 | Solid Tumors |
| NovoTTF-100L(P) | Not Applicable | Gastric Cancer |
Latest
Follow Zai Lab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.